INMED PHARMACEUTICALS INC. Finite-Lived Intangible Asset, Acquired-in-Place Leases
INMED PHARMACEUTICALS INC. (INM) had Finite-Lived Intangible Asset, Acquired-in-Place Leases of $2.93 million as of 2023-03-31, per its 10-Q filed 2023-05-15.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization › Intangible Asset, Finite-Lived, before Accumulated Amortization
us-gaap:FiniteLivedIntangibleAssetAcquiredInPlaceLeases · last filed 2023-05-15
- 2023-03-31: Finite-Lived Intangible Asset, Acquired-in-Place Leases $2.93M.
- 2022-12-31: Finite-Lived Intangible Asset, Acquired-in-Place Leases $2.93M.
- 2022-09-30: Finite-Lived Intangible Asset, Acquired-in-Place Leases $2.93M.
- 2022-06-30: Finite-Lived Intangible Asset, Acquired-in-Place Leases $2.93M.
| Period end | Finite-Lived Intangible Asset, Acquired-in-Place Leases |
|---|---|
| 2023-03-31 | $2.93M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $2.93M 10-Q · filed 2023-02-17 |
| 2022-09-30 | $2.93M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $2.93M 10-Q · filed 2023-05-15 |
| 2022-03-31 | $3.14M 10-Q · filed 2022-05-13 |
| 2021-12-31 | $3.14M 10-Q · filed 2022-02-14 |
| 2021-06-30 | $1.74M 10-K · filed 2022-09-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |